Dataset Information

Clinacanthus nutans fractions exert anti-nasopharyngeal carcinoma effects: integrating untargeted metabolomics, network pharmacology, molecular docking and experimental validation

ABSTRACT:

Background: Clinacanthus nutans (C. nutans), a Southeast Asian medicinal herb, has ethnopharmacological potential against nasopharyngeal carcinoma (NPC). This study aimed to elucidate the bioactive compounds, potential molecular targets, and regulatory pathways responsible for the anticancer activity of the Clinacanthus nutans leaves ethanol extract (E-CNL) fractions against NPC.

Methods: HPLC-Q-TOF/MS/MS and GC-MS analyses, combined with chemometric modeling, were employed to comprehensively profile the phytochemical composition of E-CNL fractions. NPC-related targets were retrieved from GEO, GeneCards, and DisGeNET, and integrated into a PPI network constructed via Cytoscape. GO and KEGG enrichment analyses were performed to characterize key targets and pathways. Molecular docking (AutoDockTools, PyMOL) was used to assess compound–target binding. Pharmacological validation was conducted using NPC cell lines (HK-1, C666-1, and CNE2).

Results: Sixty-one compounds and 794 potential targets were identified with 175 overlapping NPC-associated targets. PPI analysis highlighted ten hub genes, including TP53, STAT3, BCL2, CASP3, BCL2L1, MTOR, TNF, AKT1, ALB, and HIF1A. GO terms indicated roles in oxidative stress response, kinase regulation, phosphorylation, and MAPK cascade modulation, while KEGG analysis revealed significant associations with the PI3K–Akt, p53, TNF, FoxO, and VEGF signaling pathways. Molecular docking revealed strong affinities of the key compounds with PIK3CA, AKT1, TP53, and CDK1. In vitro assays confirmed that E-CNL fractions significantly inhibited NPC cell proliferation and migration, supporting their potential therapeutic relevance.

Conclusion: E-CNL fractions exert their anti-NPC effects through multicomponent, multi-target, and multi-pathway mechanisms. These findings provide a scientific foundation for the further exploration of E-CNL fractions as promising treatment agents for NPC.

INSTRUMENT(S): Liquid Chromatography MS - negative - reverse-phase, Liquid Chromatography MS - positive - reverse-phase, Gas Chromatography MS - positive

PROVIDER: MTBLS13610 | MetaboLights | 2026-01-05

REPOSITORIES: MetaboLights

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	a_MTBLS13610_GC-MS_positive__metabolite_profiling.txt	Txt
	a_MTBLS13610_LC-MS_negative_reverse-phase_metabolite_profiling-1.txt	Txt
	a_MTBLS13610_LC-MS_negative_reverse-phase_metabolite_profiling.txt	Txt
	a_MTBLS13610_LC-MS_positive_reverse-phase_metabolite_profiling-1.txt	Txt
	a_MTBLS13610_LC-MS_positive_reverse-phase_metabolite_profiling.txt	Txt

Items per page:

1 - 5 of 12

Similar Datasets

Project description:Osteoarthritis (OA) is a debilitating joint disorder characterized by cartilage degradation and chondrocyte homeostasis disruption. Although retinoic acid (RA) has been applied in the model preparation of OA, its target of action and signaling pathway are not clear. Leveraging a translational framework that integrates RNA-sequencing transcriptomics, network pharmacology prediction, computational ligand-receptor molecular docking, and biological experimental validation, this study systematically deciphers RA's disease-modifying targets and associated signaling circuitry in OA pathogenesis. RNA-sequencing of RA-treated chondrocytes revealed 656 differentially expressed genes (DEGs). Protein-protein interaction (PPI) network analysis and functional enrichment (GO/KEGG) highlighted key pathways, including extracellular matrix reorganization and PI3K-Akt-mediated mechanotransduction and others. Additionally, molecular docking results ranked binding affinities in descending order as follows: ACAN > SFRP2 > KANSL2 (NSL2), and so on. Network pharmacology identified 42 RA-OA shared targets, with protein-protein interaction (PPI) analysis and functionally enriched (GO/KEGG) including the Renin-angiotensin system, Neuroactive ligand-receptor interaction, and others. The molecular docking results showed a total score in descending order of MAPK14(p38α), PTGER3(PGE2-R), CA2(CACNA2D2), and so on. Five intersecting targets (CA2, ACE, PTGS1(COX-1), PGR, and EDNRA(ETAR) ) from RNA-sequencing and network pharmacology were obtained, and molecular docking was used to dock the intersecting targets to RA. The docking results demonstrated strong binding affinities, which were further validated through western blot and RT-qPCR experiments, confirming the RA-induced upregulation of the intersecting targets. These findings were accompanied by immunofluorescent evidence showing elevated levels of MMP13 and suppressed expression of COL2A1, collectively reflecting the phenotypic characteristics of OA. Our findings position CA2 and ACE as key hubs for multi-targeting. This study not only reveals possible mechanistic studies of RA in OA but also provides a drug reference for the development of drugs against OA.

Project description:Background: Triple-negative breast cancer (TNBC) urgently needs effective therapies due to limited targeted options and unfavorable outcomes. We investigated Trichosanthes kirilowii Maxim formula granules (TKM) using integrated network pharmacology, metabolomics, and molecular pharmacology to clarify potential multi-target mechanisms relevant to TNBC.Methods: Liquid chromatography coupled with mass spectrometry was employed to identify the components of TKM formula granules. Network pharmacology-based prediction was used to uncover potential mechanisms by which TKM counteracts TNBC. Potential targets were identified, and pathway enrichment analysis was performed. Subsequently, TNBC cells and 4T1 tumor-bearing mice were used to verify the molecular mechanisms of TKM.Results: We identified 151 active compounds in TKM. Through network pharmacology analysis, 214 TNBC-related targets were found, with 28 core targets, including cell cycle and apoptosis regulators MYC, TP53, AKT1, CCND1, CASP3, PIK3CA, BCL2L1, and CDC42. The compound-target-pathway-disease network showed that schisandrin binds to many treatment targets with satisfactory docking performance, especially for MYC and AKT1. Experimentally, TKM was found to significantly promote apoptosis and induce G2/M-phase cell-cycle arrest in MDA-MB-231 cells. Western blot analysis showed that TKM suppressed PI3K/AKT and Wnt/β-catenin signaling pathways. Surface plasmon resonance experiment revealed that schisandrin binds to recombinant AKT1 with an equilibrium dissociation constant (K_D) of 0.1525 mM. According to untargeted metabolomics results, TKM can regulate amino acid, glycine, serine, and threonine metabolism, mineral absorption, protein digestion and absorption, central carbon metabolism, and arginine biosynthesis to exert therapeutic effects on TNBC. All findings were consistent with predicted targets and pathways.Conclusion: This study comprehensively explores the multi-target mechanisms of TKM against TNBC using network pharmacology, molecular pharmacology, and metabolomics approaches. These findings provide a foundation for future mechanistic investigations and may support the further preclinical development of TKM-based strategies for TNBC.

Dataset Information

Clinacanthus nutans fractions exert anti-nasopharyngeal carcinoma effects: integrating untargeted metabolomics, network pharmacology, molecular docking and experimental validation

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets